Curefoods, India's largest cloud kitchen operator, has postponed its Rs 800 crore IPO plans after Sebi approval just months after receiving SEBI approval - and the reason matters more than the headline. Mutual funds resisted its Rs 4,000 crore valuation, ET reported June 8. That is not a market timing problem. That is a valuation-and-operations problem wearing a market-timing disguise.
Curefoods filed its IPO papers in June 2025 and got the green light in October. The plan was a clean debut in late 2025 or early 2026. Instead, institutional buyers pushed back hard on the price, and the company hit pause.
But the valuation standoff is only the surface layer. The underlying question for anyone who has been following this name - or is watching for the eventual public debut - is whether the business can ever justify the multiple investors are being asked to accept.
The growth is real. The losses are structural.
Curefoods generated an operating revenue of INR 745.8 Cr in FY25, up 27.4% from INR 585.1 Cr, up 27.4% from ₹585.1 crore the prior year. The company projects an annual revenue run-rate of approximately ₹1,000 crore by the end of FY25. In a sector with operated in 340... The company recorded a 21.3 percent market share and a 21.3% share of India's cloud kitchen market, that is a legitimate scale story.
But the margin math does not follow. Net loss remained almost flat at INR 169.9 Cr in the year ended March 2025 (FY25) as against INR 172.6 Cr in the previous fiscal year versus ₹172.6 crore in FY24. EBITDA margin sat at -7.5%. Its ROCE and EBITDA margin stood at -19% and -7.5%. Those are not numbers that improve with revenue growth if the cost structure doesn't bend.
To be fair, there was improvement at the operating level: narrowed its EBITDA loss to INR 82.8 Cr in FY24 from INR 275.7 Cr in FY23, resulting in a 58 percentage point improvement, a 58 percentage point margin improvement that year. But FY25 saw that leverage stall. Revenue grew 27%, and the net loss barely moved. That is what investors call margin pressure, and it is what makes institutional buyers hesitate at a ₹4,000 crore price tag.
At that valuation, Curefoods would be trading at roughly 5.4x trailing revenue. For comparison, that is a multiple usually reserved for companies showing a credible path to profitability, not ones burning ₹170 crore a year. The cheap bridge only works if the business proves the losses are compressing faster than growth slows. So far, the evidence points the other way.
The attrition problem no one is ignoring
Curefoods reported an attrition rate of 111.7% for the financial year ended March 31, 2025 (FY25). That means the company hired more people during the year than it had at the start - essentially replacing its entire workforce and then some. For a cloud kitchen operator, where kitchen execution, chef consistency, and delivery logistics are the product, this is a severe operational risk.
Cloud kitchens are not software. You cannot replace talent turnover with automation or a product update. High attrition means inconsistent food quality, rising training costs, and operational chaos - all of which eat margins and erode the brand equity that names like EatFit, Cakezone, and Yumlane have spent years building.
The competitive squeeze is real
Curefoods built its thesis on the convenience of delivery-only dining. The problem is that the Indian quick-commerce duopoly - Blinkit (By mid-2025, Blinkit had crossed 50% market share) and Zepto (~30%) - has collapsed delivery times to under 10 minutes for groceries and ready-to-eat food. When Blinkit and Zepto can deliver a meal in the same window Curefoods promises, the cloud kitchen's delivery advantage evaporates.
Curefoods filed its IPO saying it would use proceeds to expand its kitchen network, reduce debt, and grow its brand portfolio. But in a market where the two big platforms control the last-mile delivery infrastructure and dominate consumer attention, expanding kitchens feels like pouring money into a funnel whose exit is getting narrower.
So - buy the dip, or step aside?
This is a private company, so there is no stock to buy today. But for secondary market investors, pre-IPO funds, and anyone waiting for the eventual listing, the posture is clear: too early.
A postponed IPO becomes a buying opportunity only when the valuation reset outpaces the business deterioration. Here, the valuation hasn't even reset yet. The ₹4,000 crore figure still hangs over the deal. Until mutual funds are willing to write a check at a number that reflects ₹170 crore in annual losses and 112% attrition, this is not a bargain. It is an unresolved negotiation.
What would change the call
Watch three metrics when Curefoods resurfaces:
- EBITDA margin trajectory: The company needs to show quarter-over-quarter improvement from the -7.5% level. A path to breakeven within 12–18 quarters is the minimum for a defensible public listing multiple.
- Attrition normalization: If the workforce turnover doesn't come down to single-digit territory, the kitchen consistency problem will keep eating margins regardless of how many new locations open.
- Valuation discipline: A secondary round or renewed IPO process at a materially lower multiple - somewhere in the ₹2,500–3,000 crore range - would give investors real margin of safety. Anything closer to the current ₹4,000 crore tag requires proof that the loss rate is structurally declining, not just temporarily flat.
Curefoods has a real business with real scale. But scale without margin compression is not a moat - it is an expense center. The market isn't punishing the company for bad timing. It is refusing to pay for growth that hasn't yet learned to generate cash.